Literature DB >> 32701811

Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET/CT in a Patient With Primary Prostate Cancer.

Olayinka A Abiodun-Ojo1, Akinyemi A Akintayo1, Gabriel L Sica, Mehrdad Alemozaffar2, David M Schuster1.   

Abstract

F-fluciclovine is a PET radiotracer approved for detection of recurrent prostate cancer, with utility in other malignancies being investigated. We present the case of a 71-year-old man with high-risk primary prostate cancer (Gleason score 9, prostate-specific antigen 34 ng/mL) and newly diagnosed lung adenocarcinoma. As part of a clinical trial (NCT03081884), preoperative F-fluciclovine PET/CT showed localized abnormal uptake in the prostate gland with extracapsular extension. Additionally, an incidental anterior mediastinal mass measuring 2.2 × 1.8 cm demonstrated abnormal radiotracer uptake. Biopsy of the mediastinal mass confirmed invasive lung adenocarcinoma with solid and acinar patterns and high programmed death 1 ligand expression.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32701811      PMCID: PMC7609453          DOI: 10.1097/RLU.0000000000003207

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


  14 in total

1.  18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.

Authors:  Kirsten M Selnæs; Brage Krüger-Stokke; Mattijs Elschot; Frode Willoch; Øystein Størkersen; Elise Sandsmark; Siver A Moestue; May-Britt Tessem; Dag Halvorsen; Eirik Kjøbli; Anders Angelsen; Sverre Langørgen; Helena Bertilsson; Tone F Bathen
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

Review 2.  Update on 18F-Fluciclovine PET for Prostate Cancer Imaging.

Authors:  Ephraim E Parent; David M Schuster
Journal:  J Nucl Med       Date:  2018-03-09       Impact factor: 10.057

3.  Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

4.  Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.

Authors:  Rianot Amzat; Pooneh Taleghani; Daniel L Miller; Jonathan J Beitler; Leah M Bellamy; Jonathon A Nye; Weiping Yu; Bital Savir-Baruch; Adeboye O Osunkoya; Zhengjia Chen; William F Auffermann; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

5.  Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Authors:  Oluwaseun A Odewole; Funmilayo I Tade; Peter T Nieh; Bital Savir-Baruch; Ashesh B Jani; Viraj A Master; Peter J Rossi; Raghuveer K Halkar; Adeboye O Osunkoya; Oladunni Akin-Akintayo; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-18       Impact factor: 9.236

6.  Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence.

Authors:  Nghi C Nguyen; Ashok Muthukrishnan; James M Mountz
Journal:  Clin Nucl Med       Date:  2020-01       Impact factor: 7.794

7.  L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.

Authors:  Atsuki Segawa; Shushi Nagamori; Yoshikatsu Kanai; Nobuhide Masawa; Tetsunari Oyama
Journal:  Mol Clin Oncol       Date:  2012-12-20

8.  ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Authors:  K Shimizu; K Kaira; Y Tomizawa; N Sunaga; O Kawashima; N Oriuchi; H Tominaga; S Nagamori; Y Kanai; M Yamada; T Oyama; I Takeyoshi
Journal:  Br J Cancer       Date:  2014-03-06       Impact factor: 7.640

9.  Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.

Authors:  Irena Saarinen; Ivan Jambor; Mai Kim; Anna Kuisma; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Anna-Riina Koskenniemi; Ileana Montoya Perez; Peter Boström; Pekka Taimen; Heikki Minn
Journal:  EJNMMI Res       Date:  2019-05-31       Impact factor: 3.138

10.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.

Authors:  K Kaira; N Oriuchi; H Imai; K Shimizu; N Yanagitani; N Sunaga; T Hisada; S Tanaka; T Ishizuka; Y Kanai; H Endou; T Nakajima; M Mori
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.